Data Sheet 1_Sustained complete response to TMEp-CI-M platform in refractory small-cell lu

A single-case report details a 60-year-old male patient with PD-L1-negative extensive-stage small-cell lung cancer and brainstem metastasis. The patient achieved no evidence of disease for over 20 months following treatment with the TMEp-CI-M platform, which integrates stereotactic body radiotherapy, low-dose etoposide, anlotinib, checkpoint inhibition, and microbiome modulation. The report, authored by Yating Wu and licensed under CC-BY-4.0, was last updated on June 1, 2026.

Use Cases

• Analyze the efficacy of sequential tumor microenvironment priming (TMEp) based on the described treatment regimen.
• Study biomarker response (ProGRP levels) to combination therapy based on the case's reported data.
• Investigate durable response patterns in immunologically 'cold' tumors based on the described platform.
• Review adverse event profiles for combined radiotherapy, chemotherapy, and immunotherapy based on the reported Grade 1 hypothyroidism.

Strengths

• Reports a specific, detailed clinical outcome with over 20 months of disease-free survival.
• Includes concrete biomarker data, such as ProGRP levels dropping from 1803 pg/mL to 23.71 pg/mL.
• Describes a novel, multi-component therapeutic platform (TMEp-CI-M) with potential cross-cancer applicability.

Limitations

• The dataset is a single-case report (n=1), limiting statistical power and generalizability.
• Column-level data is unavailable; the primary content is a narrative PDF document.
• The data is a 644.6 KB PDF file, which is a tiny dataset with limited scope for quantitative analysis.

Provenance

Source

Yating Wu

Collection Method

Clinical case report.

Freshness

Last updated 2026-06-01 05:18:39; freshness should be verified.